CY1116931T1 - Στοματικο σκευασμα μεταδοξινης - Google Patents
Στοματικο σκευασμα μεταδοξινηςInfo
- Publication number
- CY1116931T1 CY1116931T1 CY20151101012T CY151101012T CY1116931T1 CY 1116931 T1 CY1116931 T1 CY 1116931T1 CY 20151101012 T CY20151101012 T CY 20151101012T CY 151101012 T CY151101012 T CY 151101012T CY 1116931 T1 CY1116931 T1 CY 1116931T1
- Authority
- CY
- Cyprus
- Prior art keywords
- metaxoxin
- oral preparation
- symptoms
- alcohol
- metadoxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μεθόδους και συνθέσεις μεταδοξίνης και των φυσιολογικά συμβατών δραστικών παραγώγων αυτής, και τη χρήση τους στη μείωση των συμπτωμάτων της κατανάλωσης αλκοόλ, καθώς και στην πρόληψη των συμπτωμάτων που σχετίζονται με την κατανάλωση αλκοόλ σε άτομα που το έχουν ανάγκη.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL184389A IL184389A0 (en) | 2007-07-03 | 2007-07-03 | Use of metadoxine in relief alcohol intoxication |
IL187159A IL187159A0 (en) | 2007-07-03 | 2007-11-05 | Use of metadoxine in relief of alcohol intoxication |
EP08763673.4A EP2173345B1 (en) | 2007-07-03 | 2008-07-03 | Oral formulation of metadoxine |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116931T1 true CY1116931T1 (el) | 2017-04-05 |
Family
ID=40226624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101012T CY1116931T1 (el) | 2007-07-03 | 2015-11-10 | Στοματικο σκευασμα μεταδοξινης |
Country Status (20)
Country | Link |
---|---|
US (3) | US20100256198A1 (el) |
EP (2) | EP2173345B1 (el) |
JP (2) | JP2010531872A (el) |
KR (3) | KR20150046394A (el) |
CN (2) | CN106890130A (el) |
AU (1) | AU2008272420B2 (el) |
BR (1) | BRPI0814617A2 (el) |
CA (1) | CA2691973C (el) |
CY (1) | CY1116931T1 (el) |
DK (1) | DK2173345T3 (el) |
ES (1) | ES2552717T3 (el) |
HR (1) | HRP20151202T1 (el) |
HU (1) | HUE028078T2 (el) |
IL (2) | IL187159A0 (el) |
MX (1) | MX2010000266A (el) |
PL (1) | PL2173345T3 (el) |
PT (1) | PT2173345E (el) |
RU (1) | RU2526157C2 (el) |
SI (1) | SI2173345T1 (el) |
WO (1) | WO2009004629A2 (el) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
WO2010013242A1 (en) * | 2008-07-29 | 2010-02-04 | Alcobra Ltd. | Substituted pyridoxine-lactam carboxylate salts |
KR101068686B1 (ko) * | 2009-02-17 | 2011-09-29 | 서울대학교산학협력단 | 메타독신을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
JP5770173B2 (ja) * | 2009-06-25 | 2015-08-26 | アルコブラ、リミテッドAlcobra Ltd. | 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法 |
CN102784101A (zh) * | 2012-08-06 | 2012-11-21 | 济南维尔康生化制药有限公司 | 一种美他多辛注射剂及其制备方法 |
MX2015003810A (es) * | 2012-09-26 | 2015-07-17 | Eurodrug Lab B V | Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina. |
CN103340826B (zh) * | 2013-07-05 | 2015-09-09 | 浙江震元制药有限公司 | 美他多辛注射用组合物及其制备方法 |
TW201606304A (zh) | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 測定治療反應之方法 |
US20150073023A1 (en) | 2013-09-09 | 2015-03-12 | Alcobra Ltd. | Method Of Treating Fragile X Syndrome And Related Disorders |
KR101591429B1 (ko) * | 2014-04-07 | 2016-02-04 | 강릉원주대학교산학협력단 | 신규 숙취개선 및 간보호용 조성물 |
CN103989625B (zh) * | 2014-05-15 | 2016-03-02 | 金伟华 | 一种由美他多辛作为药用成分制备的栓剂及其制备方法 |
CN103976970A (zh) * | 2014-06-06 | 2014-08-13 | 程奉平 | 美他多辛缓释片的制备方法 |
JP7312698B2 (ja) | 2016-11-18 | 2023-07-21 | オーピアント ファーマシューティカルズ, インコーポレイテッド | オピオイド過剰摂取を処置するための組成物および方法 |
KR102454958B1 (ko) | 2017-08-04 | 2022-10-17 | 글로벌 배터리 솔루션즈 엘엘씨 | 배터리 모니터 시스템 및 방법 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1286161A (en) | 1970-01-21 | 1972-08-23 | Soc D Etudes Prod Chimique | Pyridoxine mono-esters |
FR2172906A1 (en) | 1972-02-25 | 1973-10-05 | Fabre Sa Pierre | Salts of 3-pyridyl methanol derivs - vasodilators |
IT1131856B (it) * | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Composizione farmaceutica per il trattamento di intossicazioni alcooliche |
IT1131855B (it) * | 1980-06-30 | 1986-06-25 | Baldacci Lab Spa | Procedimento per la preparazione di pirrolidon carbossilato di piridossina |
JPH02138128A (ja) * | 1988-11-19 | 1990-05-28 | Eiji Amaya | 血中アルコール濃度降下薬 |
IT1244507B (it) | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
IT1263957B (it) * | 1993-02-23 | 1996-09-05 | Impiego terapeutico del pirrolidon carbossilato di piridossina | |
IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5714531A (en) * | 1996-01-22 | 1998-02-03 | Japan Polychem Corporation | Propylene resin extruded articles |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US5942530A (en) * | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
GB0007419D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Gmbh | Composition |
WO2002036126A1 (en) * | 2000-10-30 | 2002-05-10 | Lupin Limited | Rapidly disintegrating sustained release cefuroxime axetil composition |
US20020192303A1 (en) | 2001-06-01 | 2002-12-19 | Stefan Arver | Treatment of side effects associated with alcohol consumption |
WO2003003981A2 (en) | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
IL159813A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
US6541043B2 (en) * | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US6913769B2 (en) * | 2003-02-18 | 2005-07-05 | Brian Douglas Oslick | Compositions for prevention and treatment of symptoms associated with ethyl alcohol consumption |
CN1212842C (zh) * | 2003-08-20 | 2005-08-03 | 杭州容立医药科技有限公司 | 美他多辛咀嚼片及其制备方法 |
ES2235626B1 (es) * | 2003-11-10 | 2006-11-01 | Almirall Prodesfarma, S.A. | Formas de administracion masticables, no comprimidas dosificadas individualmente. |
US20050271739A1 (en) | 2004-06-08 | 2005-12-08 | Wang Xiang H | Methods and compositions for accelerating alcohol metabolism |
JP2008504295A (ja) * | 2004-06-25 | 2008-02-14 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物 |
JP2006022056A (ja) * | 2004-07-08 | 2006-01-26 | I M B Kk | 酒酔い防止剤 |
CN1301108C (zh) * | 2004-10-15 | 2007-02-21 | 山东齐都药业有限公司 | 美他多辛分散片及其制备方法 |
EP1926488A2 (en) * | 2005-09-22 | 2008-06-04 | SB Pharmco Puerto Rico Inc. | Combination of rosiglitazone and donepezil for improvement of cognitive function |
US20070248696A1 (en) * | 2006-04-25 | 2007-10-25 | Mind Sports Nutrition Inc. | Composition and method for enhancing neuromuscular facilitation and cognitive functions |
KR100877600B1 (ko) | 2006-11-30 | 2009-01-08 | 재단법인서울대학교산학협력재단 | 메타독신 및 마늘유를 유효성분으로 함유하는 알코올성지방간 및 지방간성 간염의 예방 및 치료용 약학 조성물 |
IL187159A0 (en) * | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
WO2010013242A1 (en) | 2008-07-29 | 2010-02-04 | Alcobra Ltd. | Substituted pyridoxine-lactam carboxylate salts |
JP5770173B2 (ja) * | 2009-06-25 | 2015-08-26 | アルコブラ、リミテッドAlcobra Ltd. | 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法 |
-
2007
- 2007-11-05 IL IL187159A patent/IL187159A0/en unknown
-
2008
- 2008-07-03 PL PL08763673T patent/PL2173345T3/pl unknown
- 2008-07-03 JP JP2010514251A patent/JP2010531872A/ja active Pending
- 2008-07-03 KR KR20157009784A patent/KR20150046394A/ko not_active Application Discontinuation
- 2008-07-03 CA CA2691973A patent/CA2691973C/en not_active Expired - Fee Related
- 2008-07-03 KR KR1020107002488A patent/KR20100045457A/ko active IP Right Grant
- 2008-07-03 US US12/667,272 patent/US20100256198A1/en not_active Abandoned
- 2008-07-03 PT PT87636734T patent/PT2173345E/pt unknown
- 2008-07-03 ES ES08763673.4T patent/ES2552717T3/es active Active
- 2008-07-03 WO PCT/IL2008/000917 patent/WO2009004629A2/en active Application Filing
- 2008-07-03 MX MX2010000266A patent/MX2010000266A/es active IP Right Grant
- 2008-07-03 EP EP08763673.4A patent/EP2173345B1/en not_active Not-in-force
- 2008-07-03 EP EP13178693.1A patent/EP2716288A1/en not_active Withdrawn
- 2008-07-03 HU HUE08763673A patent/HUE028078T2/en unknown
- 2008-07-03 CN CN201611027325.4A patent/CN106890130A/zh active Pending
- 2008-07-03 CN CN200880105394A patent/CN101795687A/zh active Pending
- 2008-07-03 DK DK08763673.4T patent/DK2173345T3/en active
- 2008-07-03 AU AU2008272420A patent/AU2008272420B2/en not_active Ceased
- 2008-07-03 SI SI200831526T patent/SI2173345T1/sl unknown
- 2008-07-03 RU RU2010103455/15A patent/RU2526157C2/ru not_active IP Right Cessation
- 2008-07-03 BR BRPI0814617-9A2A patent/BRPI0814617A2/pt not_active IP Right Cessation
- 2008-07-03 KR KR1020167011856A patent/KR20160054632A/ko not_active Application Discontinuation
-
2010
- 2010-03-16 IL IL204528A patent/IL204528A/en active IP Right Grant
-
2012
- 2012-07-03 US US13/541,564 patent/US8476304B2/en not_active Expired - Fee Related
-
2013
- 2013-11-20 JP JP2013239871A patent/JP5661900B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-03 US US14/678,502 patent/US9808446B2/en not_active Expired - Fee Related
- 2015-11-09 HR HRP20151202TT patent/HRP20151202T1/hr unknown
- 2015-11-10 CY CY20151101012T patent/CY1116931T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116931T1 (el) | Στοματικο σκευασμα μεταδοξινης | |
CY1118454T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CY1111354T1 (el) | Συστασεις αναστολεα ddp iv | |
CY1114988T1 (el) | Βενζοδιαζεπινη αναστολεας bromodomain | |
CY1112813T1 (el) | 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων | |
CY1119041T1 (el) | Αλκοολικες συνθεσεις που παρουσιαζουν ελαττωμενο κινδυνο ακεταλδεϋδαιμιας | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
EA201070519A1 (ru) | Соединения тропана | |
MY152710A (en) | Oral compositions containing extracts of garcinia mangostana l. and related methods | |
EA201291310A1 (ru) | Композиция ингибитора jak для местного применения | |
ECSP088904A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
MY166789A (en) | Arginine salts and their uses for the treatment of illnesses in the oral cavity | |
TR200806298A2 (tr) | Farmasötik formülasyon | |
MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
GT201200348A (es) | Composiciones farmacèuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona | |
CR20130239A (es) | Compuestos de triazolopiridina | |
BR112016006064A2 (pt) | composição de pró-dentifrício, composição com base em glicerina, e, kit para terapia da mucosa oral | |
CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
CY1110213T1 (el) | Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων | |
CO6290689A2 (es) | Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica | |
SV2010003773A (es) | 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
MY146803A (en) | Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors | |
IT1398773B1 (it) | Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico. |